Overview

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The rationale of the study is to determine: - the first dose and the titration of basal insulin - the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin Glargine